Compare SBFM & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBFM | NDRA |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 5.0M |
| IPO Year | N/A | 2017 |
| Metric | SBFM | NDRA |
|---|---|---|
| Price | $1.17 | $3.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 36.6K | 27.5K |
| Earning Date | 03-31-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,323,742.00 | N/A |
| Revenue This Year | $10.26 | N/A |
| Revenue Next Year | $32.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.24 | N/A |
| 52 Week Low | $1.15 | $2.90 |
| 52 Week High | $3.90 | $11.96 |
| Indicator | SBFM | NDRA |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 34.60 |
| Support Level | $1.15 | $3.48 |
| Resistance Level | $1.23 | $3.78 |
| Average True Range (ATR) | 0.06 | 0.34 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 10.00 | 18.99 |
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.